Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

10837	Companies
235301	Keywords
164225	Articles
126039	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 04/08/2024 at 07:00, 2 years 4 months ago

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Newron Pharmaceuticals presented data from study 014/015 and evenamide clinical development outlook at SIRS 2024 Congress, showcasing potential for new TRS treatment options

Clinical Development Newron Pharmaceuticals Evenamide Study 014/015 Schizophrenia International Research Society
BRIEF

published on 03/19/2024 at 07:05, 2 years 4 months ago

Newron Pharmaceuticals S.p.A. Announces 2023 Financial Results and Provides Outlook for 2024

2024 Outlook Financial Results 2023 Newron Pharmaceuticals Evenamide Development Xadago Safinamide
BRIEF

published on 03/19/2024 at 07:05, 2 years 4 months ago

Newron Pharmaceuticals SpA annonce ses résultats financiers pour 2023 et fournit des perspectives pour 2024

Perspectives 2024 Résultats Financiers 2023 Produits Pharmaceutiques Newron Xadago Safinamide Développement D'Evenamide
PRESS RELEASE

published on 03/19/2024 at 07:00, 2 years 4 months ago

Newron presents 2023 financial results and provides 2024 outlook
Newron Pharmaceuticals S.p.A. presents 2023 financial results and 2024 outlook, including advancements in schizophrenia treatment and strategic partnerships

Financial Results 2024 Outlook Partnerships Newron Pharmaceuticals Schizophrenia Treatment
BRIEF

published on 03/15/2024 at 07:05, 2 years 5 months ago

Newron Pharmaceuticals S.p.A. Announces Amended Repayment Agreement with European Investment Bank

European Investment Bank Newron Pharmaceuticals Financing Agreement Evenamide CNS Treatments
BRIEF

published on 03/15/2024 at 07:05, 2 years 5 months ago

Newron Pharmaceuticals SpA annonce un accord de remboursement modifié avec la Banque européenne d'investissement

Produits Pharmaceutiques Newron Evenamide Banque Européenne D'investissement Accord De Financement Traitements Du SNC
PRESS RELEASE

published on 03/15/2024 at 07:00, 2 years 5 months ago

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Newron Pharmaceuticals S.p.A. agrees with EIB to extend repayment dates of 2018 financing agreement tranches after pipeline milestones

European Investment Bank Financing Agreement Evenamide Newron Pharmaceuticals S.p.A. Loan Repayment Dates
BRIEF

published on 03/14/2024 at 18:37, 2 years 5 months ago

Newron Pharmaceuticals Secures Up to EUR 15 Million in Funding Through New Share Issuance

Share Issuance Biopharmaceuticals Investment Agreement Newron Pharmaceuticals CNS Therapies
BRIEF

published on 03/14/2024 at 18:37, 2 years 5 months ago

Newron Pharmaceuticals obtient jusqu'à 15 millions d'euros de financement grâce à l'émission de nouvelles actions

Émission D'actions Produits Biopharmaceutiques Accord D'investissement Produits Pharmaceutiques Newron Thérapies Du SNC
PRESS RELEASE

published on 03/14/2024 at 18:32, 2 years 5 months ago

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
Newron Pharmaceuticals S.p.A. enters a subscription agreement for up to 2.05 million new shares, aiming to raise EUR 15.0 million. The investment supports CNS therapies development

Subscription Agreement Newron Pharmaceuticals Newly Issued Shares EUR 15.0 Million CNS Therapies Development

Accesswire

Published on 08/15/2026 at 00:50, 2 days ago

Revive Therapeutics Reports Grant of Options
Published on 08/15/2026 at 00:15, 2 days 1 hour ago

Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 2 days 1 hour ago

AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:25, 2 days 2 hours ago

NuRAN Wireless Closes $7.6 Million Financing
Published on 08/14/2026 at 23:00, 2 days 2 hours ago

Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

View all ACCESSWIRE

EQS Group

Published on 08/16/2026 at 19:40, 5 hours 48 minutes ago

APIC delivers 55% EBITDA growth in the first half of 2026, reaching USD 44 million
Published on 08/16/2026 at 13:40, 11 hours 48 minutes ago

Ajax says goodbye to Godts with a classy message in Paris: THE FUTURE BELONGS TO YOUNG GODTS
Published on 08/16/2026 at 09:45, 15 hours 43 minutes ago

Ragnarok Zero: Global Set to Officially Launch on August 18
Published on 08/16/2026 at 06:15, 19 hours 13 minutes ago

GARVEE met en avant les essentiels pour la maison et le jardin à l’approche de la transition entre la fin de l’été et le début de l’automne
Published on 08/16/2026 at 06:15, 19 hours 13 minutes ago

Garvee Spotlights Home & Garden Essentials for the Late-Summer to Early-Autumn Transition

Les Echos

Published on 08/13/2026 at 18:00, 3 days 7 hours ago

Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 5 days 7 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 5 days 7 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 6 days 7 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 6 days 7 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026

View all LES ECHOS COMFI WIRE